Project Grant HT94252310833
Award Date 9/1/23
Completion Date 8/31/26
Dollars Obligated $1.3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19111, USA
Similar Awards
- The Institute For Cancer Research at Temple University received a $187,000 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The two-year award, which runs from April 1, 2021 through March 31, 2023, will support research into therapeutic targeting of P300/CBP in clear cell renal cell carcinoma. The Military Medical Research and Development program aims to transform military and public...
- The U.S. Defense Health Agency awarded a $700,788 Project Grant to The Institute For Cancer Research, a non-profit subsidiary of Temple University, under the Military Medical Research and Development program (CFDA 12.420). The funding supports a 3-year research project to study the targeting of the nuclear necroptosis pathway in the pancreatic cancer microenvironment. As a prime grantee, The Institute For Cancer Research will conduct preclinical testing, biomarker analysis, and other specialized...
- The U.S. Defense Health Agency awarded a $1,880,000 Project Grant to The Institute for Cancer Research, a non-profit subsidiary of Temple University, under the Military Medical Research and Development program (CFDA 12.420). The funding will support a 3-year research project to study the SRPK1-AKT signaling axis in endometrial cancer. As a prime grantee, The Institute for Cancer Research will conduct preclinical testing and analysis to develop new approaches for cancer prevention and...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded The Institute For Cancer Research a $1,959,353 project grant effective September 1, 2025 through August 31, 2029, under the Military Medical Research and Development program (CFDA 12.420). This award supports clinical research investigating pembrolizumab maintenance therapy following enfortumab vedotin/pembrolizumab induction treatment in front-line metastatic urothelial carcinoma. The research will be conducted at the...
- This $769,073 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research to define and target cancer cell-intrinsic vulnerabilities in renal cell carcinoma. The grant was awarded to the Royal Institution for the Advancement of Learning / McGill Office of Sponsored Research Division, a private university affiliated with McGill University in Montreal, Canada. The research will be conducted from August 1, 2024...
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $999,096.00 to The University of Texas Southwestern Medical Center to conduct research on "Targeting DNA Damage Response to Treat Clear Cell Renal Cell Carcinoma." The award period runs from July 1, 2024 to June 30, 2028. The research aims to develop new treatments for clear cell renal cell carcinoma, a type of kidney cancer, by investigating...
- This $1,096,866 project grant was awarded on August 15, 2023 by the Defense Health Agency under the Department of Defense's Military Medical Research and Development program (CFDA 12.420). The grant, titled "TARGETING BRANCHED CHAIN AMINO ACIDS IN KIDNEY CANCER," will be carried out by The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, over a 3-year period ending on August 14, 2026. The funding supports biomedical...
- This Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Texas Southwestern Medical Center. The $1,312,000 grant, with a period of performance from July 1, 2024 to June 30, 2028, will support research on biomarkers and mechanisms of acquired resistance to immunotherapy for renal cell carcinoma. This work aims to improve understanding and treatment of this form of kidney cancer, which is a...
- This federal Project Grant award for $968,904.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), is supporting research at the University of Texas Southwestern Medical Center (UT Southwestern) to target the DNA damage response as a potential treatment for clear cell renal cell carcinoma. The project will be conducted at UT Southwestern's facilities in Dallas, Texas over a 4-year period from July 1, 2024 to June 30, 2028. This...
- This $834,798 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports PET imaging research of HIF 2A in renal cancer at The University of Texas Southwestern Medical Center in Dallas, Texas. The research project aims to develop new diagnostic and treatment approaches for kidney cancer, which is a key focus area for this Defense Department program. The award will fund basic, translational, and clinical research...